Lower-Risk Myelodysplastic Syndromes (LR-MDS): Highlights from EHA 2024 - Episode 3
Frontline Therapy for Lower-Risk MDS: Global Perspectives and Treatment Selection Strategies
The experts describe their strategies for selecting first-line treatments in lower-risk myelodysplastic syndrome patients, focusing on the key factors that inform their sequencing decisions in frontline therapy.
Video Player is loading.
- Dr Garcia-Manero to panelist: Please outline your current approach to 1L treatment selection for patients with lower-risk MDS.
- What factors guide your frontline selection of therapy?
- How does your approach compare between U.S. and non-U.S. physicians?
Related Content:
